Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α

Caroline Hasselbalch Riley, Morten Krogh Jensen, Marie Klinge Brimnes, Hans Carl Hasselbalch, Ole Weis Bjerrum, Per Thor Straten, Inge Marie Svane

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

Recent reports have described complete or major molecular remission in patients with polycythemia vera after long-term treatment with the immunomodulatory agent IFN-α2. Accordingly, there are reasons to believe that the immune system is a key player in eradicating the JAK2 mutated clone in these patients. Foxp3+ regulatory T cells play a pivotal role in maintaining immune homeostasis and, importantly, preventing immune reactivity to self-antigens; however, their suppressive activity can compromise an effective antitumor immune response, and high frequencies of regulatory T cells in peripheral blood have been reported in both hematologic and solid cancers. We have analyzed the number, phenotype, and function of circulating CD4 +CD25+Foxp3+ T cells in patients with chronic myeloproliferative neoplasms. Surprisingly, we found a marked expansion of this subset of lymphocytes in patients treated with IFN-α2 (13.0%; 95% confidence interval [CI] 10.8% to 15.2%) compared with healthy donors (6.1%; 95% CI 4.9% to 7.2%), patients with untreated chronic myeloproliferative neoplasms (6.9%; 95% CI 5.8% to 7.4%), or patients treated with hydroxyurea (5.8%; 95% CI 4.3% to 7.4%; P < .0001).

OriginalsprogEngelsk
Sider (fra-til)2170-2173
Antal sider4
TidsskriftBlood
Vol/bind118
Udgave nummer8
DOI
StatusUdgivet - 25 aug. 2011

Fingeraftryk Udforsk hvilke forskningsemner 'Increase in circulating CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α' indeholder.

Citationsformater